<DOC>
	<DOCNO>NCT00003882</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness anhydrovinblastine treat patient advanced recurrent solid tumor .</brief_summary>
	<brief_title>Anhydrovinblastine Treating Patients With Advanced Recurrent Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose assess toxicity anhydrovinblastine patient advance refractory solid tumor . II . Assess safety , pharmacokinetics , efficacy treatment regimen patient population . OUTLINE : This dose escalation study . Patients receive anhydrovinblastine IV 1 hour day 1 . Courses repeat every 3 week . Treatment continue absence disease progression unacceptable toxicity . The dose anhydrovinblastine escalate cohort 1-6 patient maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose limit toxicity . Patients follow 1 month treatment , monthly death . PROJECTED ACCRUAL : Approximately 30 patient accrue study within 8 month .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced solid tumor unresponsive exist therapy curative therapy exist No hematologic malignancy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : SGOT SGPT great 2.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN ( except bone metastasis ) PT PTT great ULN Bilirubin great ULN Renal : Creatinine great ULN OR Creatinine clearance least 60 mL/min Cardiovascular : No congestive heart failure , angina pectoris ( even medically control ) , uncontrolled hypertension , arrhythmia , elevate CPK recent EKG change At least one year since myocardial infarction Neurologic : No history neurologic psychiatric disorder ( e.g. , dementia , seizure ) No concurrent peripheral neuropathy great grade 1 Other : Not pregnant nursing Fertile patient must use effective contraception No active infection No active pancreatitis Amylase great upper limit normal No serious systemic disease PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy recover No concurrent immunotherapy No concurrent colony stimulate factor ( unless evidence neutropenic infection ) Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosourea mitomycin ) Prior taxanes vinca alkaloid allow recovery ( exclude alopecia grade peripheral neuropathy great grade 1 ) No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover At least 6 week since prior extensive radiotherapy great 20 % bone marrow No concurrent radiotherapy Surgery : Not specify Other : No concurrent experimental drug At least 30 day since investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>